Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10225572 | Schizophrenia Research | 2018 | 4 Pages |
Abstract
Findings suggest that deficit schizophrenia subtype is associated with increased inflammation and immunotherapies may be a novel target for negative symptoms.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
David R. Goldsmith, Ebrahim Haroon, Andrew H. Miller, Gregory P. Strauss, Peter F. Buckley, Brian J. Miller,